Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus

Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2018
Cargando información sobre las referencias
Prospective, single center, double-blind, randomized pharmacodynamic experimental study. The study will enroll 150 subjects with ASCVD on optimal statin therapy as per physician and Diabetes Mellitus (DM) undergoing elective Percutaneous Coronary Intervention (PCI). Eligible patients will be randomized for 30 day treatment to either 1) evolocumab 420 mg ; or 2) placebo.
Epistemonikos ID: d477c5f5478c5e43994d280455b48c0ea3ce145c
First added on: May 21, 2024